When a large company purchases a capability instead of building it, the transaction says as much about the organization as about the market. Between March and June of this year, three of the largest food companies in the world each acquired a complete nutrition brand, paying significant multiples to acquire the businesses at a premium. Complete nutrition is a sector based on protein density, fiber and formulations engineered to deliver a full nutritional load in a smaller volume of food.
In short, three separate boards, within four months, concluded that the fastest route into that capability ran through someone else’s balance sheet. Beneath the portfolio logic also sits a talent conclusion. The formulation science and direct-to-consumer fluency leaders possess at those brands were not present internally and building them was neither cost nor time effective.
The market reorganized in 18 months
In January 2025, 9% of US households included someone taking a GLP-1 medication. By May of this year, the share more than doubled to 21%.¹ Adoption ran flat across income levels and nearly even between men and women, which pulled the category out of the niche it was assumed to occupy. Then the constraints fell away. The FDA approved the first GLP-1 pill without food or water timing restrictions on April 1, 2026. Medicare opened a pilot three months later that placed several of these medications at a $50 monthly copay for eligible enrollees. The needle, the price and the coverage were the three things holding this market back, and all three loosened inside a single quarter.
The retail industry anticipated contraction. Suppressed appetite was expected to translate directly into smaller baskets and lower trip value, and category plans were written accordingly. Measured behavior has contradicted that expectation. Shoppers using these medications make fewer store visits while spending more per visit and more across a full year than shoppers who do not. Expenditure shifted rather than declined, away from sweets and sugary drinks and toward protein, fiber and fresh food. Households with a GLP-1 user represent 4.5% of the total and drove 43% of sales growth in products making muscle-health claims.²
Conventional category reporting would traditionally show muscle-health claims growing and attribute the gain to a broad wellness trend. The actual driver is a small cohort whose eating is governed by a medication. This differentiator creates unique implications for growth durability and purchase justification. Category leaders have been trained to address the legacy segment, but the spoils are going to those who serve this new market.
Measurable health changed who is accountable
The medication accounts for only half of the change. Health became personally measurable at consumer prices in March 2024, when the FDA cleared the first over-the-counter continuous glucose monitor, followed by a second that June. A sensor that once required a prescription now costs approximately $50 and reports in real time via smart devices and wearables. Additionally, Oura purchased a glucose-monitoring company, Whoop added blood testing through a diagnostics partner and Garmin built nutrition tracking directly into its app. These devices no longer describe behavior; they steer it. Wearable health monitoring correlates with higher consumption of water, protein and fresh produce.²
Label-scanning applications completed the shift. With roughly one in four consumers scanning products, 87% say they would return a product to the shelf if the app flags its ingredients.² This means a packaging label is now audited by an instrument both the manufacturer and an organization’s marketing team do not control, and it puts a burden on the product approver. The executive accountable for a health claim needs the credentials to defend it in front of a regulator, a retailer and a scanning algorithm, none of which are persuaded by a brand story.
The seats under pressure
The incumbent response is visible on shelves. Nestlé reached the market first with Vital Pursuit, portioned for a reduced appetite and fortified against the muscle loss and nutrient shortfalls that follow eating less. PepsiCo put ten grams of protein into a bag of Doritos and 22 grams into a Starbucks coffee, while also marketing a Propel line explicitly toward GLP-1 users. Kraft Heinz launched a protein version of mac and cheese in March 2026 and raised research and development spending by roughly 20% under a new Chief Executive who arrived in January 2026.
Each move rests on a capability the previous era treated as optional. Portioning a meal for a suppressed appetite without stranding the eater in a nutritional deficit is applied nutrition science, and it belongs to an innovation leader who can hold a conversation with a dietitian and a plant manager in the same afternoon. Selling a smaller basket at a higher price is a judgment most consumer packaged goods P&L leaders have not recently made, since the industry spent decades optimizing volume in the opposite direction. Raising research spending by a fifth in a soft year is a capital allocation with which the board must agree and requires a chief executive able to argue for it under pressure.
Finding leaders who can navigate this significant change requires a diligent approach to identifying, assessing and recruiting them. They are working in clinical and medical nutrition, sports nutrition, supplements and pharmaceutical research. Many have never received a call from a consumer-packaged goods company. A search specifically calibrated to identify packaged goods pedigrees screens them out on the first pass, which is why the seat stays open too long and the best talent stays idle.
Reading the turnover at the topHouseholds with a GLP-1 user are projected to account for 35% of US food and beverage units sold by 2030, with half of the people who stop taking the medication (without modifying their eating habits or incorporating exercise) likely to regain weight.³ However, the industry appears to be betting that the market for households with GLP-1 users will continue to grow. With that trajectory, Nestlé, Unilever, Kraft Heinz and Conagra all changed Chief Executives within the past 12 months, and more are expected to come. The turnover does not stop at the top; it cascades through the rest of the C-suite and down to the SVP and VP ranks. Each departure had a proximate cause of its own, and while none were specifically attributed to GLP-1s, all share a growth model built on pricing power that has stopped producing targeted growth at the same moment demand has reorganized around measurable health. Boards are following the same logic in their own composition. As they replace retiring members or add new expertise, they are recruiting from outside the industry and assembling a wider range of competencies than the traditional slate offered, a shift driven by the capabilities the business now lacks rather than by any failure of execution. The companies moving now are not forecasting this market. They are staffing for the one they intend to build. |
SOURCES
(1) PwC analysis of Numerator data, May 2026. | (2) NIQ, 2026. | (3) Circana, 2025.
